Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 3Withdrawn 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 9Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Stomach Neoplasms 1Solid Tumors 1Solid Cancers 1Skin Diseases 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × ipatasertib × Clear all
NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Hoffmann-La Roche

Phase 1 Completed
51 enrolled 20 charts
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡